Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating crucial clinical data in Fate Therapeutics’ dense SEC reports can feel like searching for a single nucleotide in a genome. Trial updates, cash-runway projections, even FDA feedback hide inside technical language that spans hundreds of pages. If you’ve ever asked, “How do I read Fate Therapeutics’ 10-K?” or “Where are Fate Therapeutics insider trading Form 4 transactions listed?”, you know the challenge.
Stock Titan’s AI bridges that gap. Our platform delivers real-time alerts the moment a Fate Therapeutics quarterly earnings report 10-Q filing or an 8-K material event hits EDGAR. AI-powered summaries extract R&D spend, enrollment status, and partnership terms, offering Fate Therapeutics SEC filings explained simply. Click once to view Fate Therapeutics Form 4 insider transactions in real-time and spot executive stock transactions before the market reacts.
Each document is mapped to the questions investors actually ask: the annual report 10-K simplified shows cash burn and pipeline runway; the proxy statement executive compensation reveals milestone-based pay structures; 8-K material events explained highlight clinical holds or breakthrough-therapy designations; insider trading forms outline sentiment shifts. With our Fate Therapeutics earnings report filing analysis, you can compare sequential trial costs, monitor dilution risk, and evaluate strategic collaborations—all without wading through biotech jargon. Start understanding Fate Therapeutetics SEC documents with AI today and turn complex disclosures into actionable insight.
Fate Therapeutics reported Q3 2025 results. Collaboration revenue was $1.7 million, down from $3.1 million a year ago, reflecting lower recognition under its Ono collaboration. Operating expenses fell to $36.5 million from $55.5 million as R&D and G&A were reduced. Net loss narrowed to $32.3 million from $47.7 million, and loss per share improved to $0.27 from $0.40.
Liquidity and cash flows: Cash and cash equivalents were $40.6 million, with short-term investments of $174.8 million and long-term investments of $10.3 million. Total current assets were $221.3 million. Net cash used in operations for the nine months was $82.8 million, partially offset by $83.5 million net inflows from investment activity and $3.8 million from a CIRM award.
Operational updates: The company implemented an August 2025 restructuring, recording $1.1 million in severance and related costs. It recognized $1.7 million in Q3 revenue and $5.3 million year-to-date under the Ono arrangement, with committed funding through June 2026. As of November 6, 2025, 115,352,289 common shares were outstanding.
Fate Therapeutics, Inc. (FATE) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The disclosure was provided under Item 2.02 (Results of Operations and Financial Condition) and is being furnished, not filed, under the Exchange Act. The report was signed by President and Chief Executive Officer Bahram Valamehr.
Fate Therapeutics (FATE) reported an early clinical update for FT819, its off-the-shelf, CD19-targeted CAR T-cell candidate, in moderate-to-severe systemic lupus erythematosus. As of the September 25, 2025 data cut-off, 10 patients received a single FT819 dose in a Phase 1 study and data were highlighted at ACR Convergence 2025.
The trial evaluates FT819 with either less‑intensive conditioning (cyclophosphamide or bendamustine) or no conditioning. In the less‑intensive arm, the company observed rapid, sustained CD19+ B‑cell depletion that correlated with dose, followed by emergence of naïve B cells beyond baseline, consistent with an immune reset and reduction in disease burden. Without conditioning, reductions in CD19+ B cells and expanded B‑cell clones were seen, alongside improvements in disease activity scores.
Fate also initiated independent dose‑expansion cohorts in AAV, IIM, and SSc, and is engaging the FDA under its RMAT designation to align on a registrational study design with a goal to start a pivotal study in 2026.
Fate Therapeutics (FATE)10/20/2025. The CFO was granted 75,000 restricted stock units at $0.00, which vest 25% on November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029. The CFO also received a stock option for 375,000 shares at an exercise price of $1.54, vesting 25% on October 20, 2026 and monthly thereafter for 36 months, expiring on October 20, 2035. Following the transactions, the filing lists 75,000 common shares and 375,000 options beneficially owned.
Fate Therapeutics (FATE) filed a Form 3, the initial statement of beneficial ownership for its Chief Financial Officer under Section 16. The filing states that no securities are beneficially owned by the reporting person as of the event date 10/20/2025. The form was filed by one reporting person, with a Power of Attorney on file (Exhibit 24) and signed by Cindy Tahl, as Attorney-in-Fact on 10/21/2025.
Fate Therapeutics filed a Form S-8 to register 1,750,000 additional shares of common stock for issuance under its Amended and Restated Inducement Equity Plan.
The Board approved the increase on October 13, 2025, adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The filing uses General Instruction E to register additional securities and incorporates the prior S-8 (File No. 333-253459).
Pursuant to Rule 416(a), the registration also covers an indeterminate number of additional shares for anti‑dilution and other adjustments.
Fate Therapeutics (FATE) reported board and leadership changes. On October 10, 2025, John D. Mendlein and Neelufar Mozaffarian notified the company of their resignations from the Board, effective October 13, 2025. The company stated both resignations were voluntary and not due to any disagreement on operations, practices, or policies. Following these changes, the Board size was reduced from 10 to 8 directors, effective October 13, 2025.
On October 13, 2025, the Board approved the appointment of Kamal Adawi, M.S., M.B.A., as Chief Financial Officer, effective October 20, 2025. He was also designated principal financial officer and principal accounting officer, replacing Bahram Valamehr in those roles; Dr. Valamehr continues as Director and as President and Chief Executive Officer. The company furnished a press release on October 14, 2025 announcing Mr. Adawi’s appointment.
Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they collectively hold 2,274,020.09 shares of Fate Therapeutics common stock, representing 2.0% of the class. The cover pages report shared voting power of 2,273,623.09 shares and shared dispositive power of 2,274,020.09 shares.
The filing includes a joint filing agreement (Exhibit 99.1) and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. (Exhibit 99.2). The filing further certifies the securities are held in the ordinary course of business and not for the purpose of changing control. The statement is signed by Veronica Mupazviriwo as attorney-in-fact on behalf of both reporting persons.
Fate Therapeutics (FATE) reported that on August 7, 2025 its Board approved a corporate restructuring to streamline operations, reduce operating expenses and extend the company’s cash runway. The company committed to a reduction in total workforce of approximately 12% and informed affected employees on August 12, 2025.
The company expects the reduction-in-force to complete in the third quarter of 2025 and estimates it will incur charges of approximately $0.9 million to $1.2 million for severance and other employee termination-related costs. A press release with the quarter-end results is attached as Exhibit 99.1, and the information is furnished, not filed, under the Exchange Act.
FAQ
What is the current stock price of Fate Therapeutic (FATE)?
What is the market cap of Fate Therapeutic (FATE)?
